Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global Partners LP

53.57
-0.2563-0.48%
Volume:19.42K
Turnover:1.04M
Market Cap:1.80B
PE:22.62
High:54.13
Open:53.60
Low:52.76
Close:53.83
Loading ...

Why Global Partners (GLP) is Skyrocketing So Far In 2025?

Insider Monkey
·
04 Feb

Global Partners (GLP) Soars 6.8%: Is Further Upside Left in the Stock?

Zacks
·
31 Jan

Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024

TIPRANKS
·
31 Jan

Ares Management's Acquisition of GLP's International Business Gets European Commission Clearance

MT Newswires Live
·
30 Jan

Lexaria CEO says FY25 R&D will ‘remain concentrated’ on GLP-1 investigations

TIPRANKS
·
30 Jan

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

GlobeNewswire
·
30 Jan

Global Partners to Pay Q4 Distribution of $0.74 a Unit, Payable Feb. 14 to Holders of Record on Feb. 10

MT Newswires Live
·
30 Jan

TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s

TIPRANKS
·
29 Jan

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Business Wire
·
29 Jan

Press Release: Global Partners Declares Fourth-Quarter 2024 Cash Distribution of $0.7400 on Common Units

Dow Jones
·
29 Jan

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Zacks Small Cap Research
·
28 Jan

GLP J-REIT to Acquire Preferred Securities for Redevelopment Project

MT Newswires Live
·
28 Jan

GLP J-REIT Revises Narashino II Redevelopment Plan to Address Rising Costs

TIPRANKS
·
27 Jan

GLP J-REIT Acquires Preferred Securities with No Operational Impact

TIPRANKS
·
27 Jan

Allurion Technologies to initiate GLP-1 study optimizing for muscle mass

TIPRANKS
·
24 Jan

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Business Wire
·
24 Jan